Troponin I-interacting protein kinase - A novel cardiac-specific kinase, emerging as a molecular target for the treatment of cardiac disease

Circulation Journal

Volumn 78, Issue 7, 2014, Pages 1514-1519

  Lal, Hind ^a   Ahmad, Firdos ^a   Parikh, Shan ^a   Force, Thomas ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute coronary syndrome; Acute myocardial infarction; Ischemic heart disease; Reperfusion

Indexed keywords

ALPHA ACTIN; INTEGRIN LINKED KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOCYTE ENHANCER FACTOR 2; MYOSIN BINDING PROTEIN C; PEROXIREDOXIN 3; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR TBX5; TROPONIN I; TROPONIN I INTERACTING PROTEIN KINASE; UNCLASSIFIED DRUG; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; TNNI3K PROTEIN, HUMAN; TNNI3K PROTEIN, MOUSE;

APOPTOSIS; ATRIOVENTRICULAR CONDUCTION; BIOINFORMATICS; CARDIOMYOPATHY; CELL DIFFERENTIATION; CLINICAL TRIAL (TOPIC); DISEASE COURSE; GENETIC ASSOCIATION; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART INFARCTION SIZE; HEART INJURY; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REPERFUSION INJURY; REVIEW; VIRUS MYOCARDITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL DEATH; ENZYMOLOGY; GENETICS; HEART MITOCHONDRION; HEART MUSCLE; HEART MUSCLE CELL; METABOLISM; MOUSE; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY;

ANIMALS; CELL DEATH; HUMANS; MAP KINASE KINASE KINASES; MICE; MITOCHONDRIA, HEART; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 84903152646     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0543     Document Type: Review

References (39)

1. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: A neglected therapeutic target. J Clin Invest 2013; 123: 92-100.
2. Gerczuk PZ, Kloner RA. An update on cardioprotection: A review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J Am Coll Cardiol 2012; 59: 969-978.
3. Kloner RA. Current state of clinical translation of cardioprotective agents for acute myocardial infarction. Circ Res 2013; 113: 451-463.
4. Minamino T. Cardioprotection from ischemia/reperfusion injury: Basic and translational research. Circ J 2012; 76: 1074-1082.
5. Frohlich GM, Meier P, White SK, Yellon DM, Hausenloy DJ. Myocardial reperfusion injury: Looking beyond primary pci. Eur Heart J 2013; 34: 1714-1722.
6. Vagnozzi RJ, Gatto GJ Jr, Kallander LS, Hoffman NE, Mallilankaraman K, Ballard VL, et al. Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heart. Sci Transl Med 2013; 5: 207ra141.
7. Abraham DM, Marchuk DA. Inhibition of the cardiomyocyte-specific troponin I-interacting kinase limits oxidative stress, injury, and adverse remodeling due to ischemic heart disease. Circ Res 2014; 114: 938-940.
8. Wang X, Wang J, Su M, Wang C, Chen J, Wang H, et al. TNNI3K, a cardiac-specific kinase, promotes physiological cardiac hypertrophy in transgenic mice. PLoS One 2013; 8: e58570, doi:org/10.1371/ journal.pone.0058570.
9. Tang H, Xiao K, Mao L, Rockman HA, Marchuk DA. Overexpression of TNNI3K, a cardiac-specific MAPKKK, promotes cardiac dysfunction. J Mol Cell Cardiol 2013; 54: 101-111.
10. Lai ZF, Chen YZ, Feng LP, Meng XM, Ding JF, Wang LY, et al. Overexpression of TNNI3K, a cardiac-specific MAP kinase, promotes P19CL6-derived cardiac myogenesis and prevents myocardial infarction-induced injury. Am J Physiol Heart Circ Physiol 2008; 295: H708-H716.
11. Wheeler FC, Tang H, Marks OA, Hadnott TN, Chu PL, Mao L, et al. TNNI3K modifies disease progression in murine models of cardiomyopathy. PLoS Genet 2009; 5: e1000647, doi:org/10.1371/ journal.pgen.1000647.
12. Zhao Y, Meng XM, Wei YJ, Zhao XW, Liu DQ, Cao HQ, et al. Cloning and characterization of a novel cardiac-specific kinase that interacts specifically with cardiac troponin I. J Mol Med (Berl) 2003; 81: 297-304.
13. Wang H, Chen C, Song X, Chen J, Zhen Y, Sun K, et al. Mef2c is an essential regulatory element required for unique expression of the cardiac-specific CARK gene. J Cell Mol Med 2008; 12: 304-315.
14. Hannigan GE, McDonald PC, Walsh MP, Dedhar S. Integrin-linked kinase: Not so 'pseudo' after all. Oncogene 2011; 30: 4375-4385.
15. Hannigan GE, Coles JG, Dedhar S. Integrin-linked kinase at the heart of cardiac contractility, repair, and disease. Circ Res 2007; 100: 1408-1414.
16. Lal H, Verma SK, Foster DM, Golden HB, Reneau JC, Watson LE, et al. Integrins and proximal signaling mechanisms in cardiovascular disease. Front Biosci 2009; 14: 2307-2334.
17. Edmondson DG, Lyons GE, Martin JF, Olson EN. MEF2 gene expression marks the cardiac and skeletal muscle lineages during mouse embryogenesis. Development 1994; 120: 1251-1263.
18. Olson EN, Perry M, Schulz RA. Regulation of muscle differentiation by the MEF2 family of MADS box transcription factors. Dev Biol 1995; 172: 2-14.
19. Lin Q, Schwarz J, Bucana C, Olson EN. Control of mouse cardiac morphogenesis and myogenesis by transcription factor Mef2c. Science 1997; 276: 1404-1407.
20. Xu J, Gong NL, Bodi I, Aronow BJ, Backx PH, Molkentin JD. Myocyte enhancer factors 2a and 2c induce dilated cardiomyopathy in transgenic mice. J Biol Chem 2006; 281: 9152-9162.
21. van Oort RJ, van Rooij E, Bourajjaj M, Schimmel J, Jansen MA, van der Nagel R, et al. Mef2 activates a genetic program promoting chamber dilation and contractile dysfunction in calcineurin-induced heart failure. Circulation 2006; 114: 298-308.
22. Feng Y, Liu DQ, Wang Z, Liu Z, Cao HQ, Wang LY, et al. AOP-1 interacts with cardiac-specific protein kinase TNNI3K and downregulates its kinase activity. Biochemistry (Mosc) 2007; 72: 1199-1204.
23. Immenschuh S, Baumgart-Vogt E. Peroxiredoxins, oxidative stress, and cell proliferation. Antioxid Redox Signal 2005; 7: 768-777.
24. Rigoulet M, Yoboue ED, Devin A. Mitochondrial ROS generation and its regulation: Mechanisms involved in H(2)O(2) signaling. Antioxid Redox Signal 2011; 14: 459-468.
25. Wang L, Wang H, Ye J, Xu RX, Song L, Shi N, et al. Adenovirusmediated overexpression of cardiac troponin I-interacting kinase promotes cardiomyocyte hypertrophy. Clin Exp Pharmacol Physiol 2011; 38: 278-284.
26. Yajima T, Knowlton KU. Viral myocarditis: From the perspective of the virus. Circulation 2009; 119: 2615-2624.
27. Corsten MF, Schroen B, Heymans S. Inflammation in viral myocarditis: Friend or foe? Trends Mol Med 2012; 18: 426-437.
28. Dennert R, Crijns HJ, Heymans S. Acute viral myocarditis. Eur Heart J 2008; 29: 2073-2082.
29. Bowles NE, Ni J, Kearney DL, Pauschinger M, Schultheiss HP, McCarthy R, et al. Detection of viruses in myocardial tissues by polymerase chain reaction: Evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol 2003; 42: 466-472.
30. Esfandiarei M, McManus BM. Molecular biology and pathogenesis of viral myocarditis. Annu Rev Pathol 2008; 3: 127-155.
31. Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A, et al. Update on myocarditis. J Am Coll Cardiol 2012; 59: 779-792.
32. Wiltshire SA, Leiva-Torres GA, Vidal SM. Quantitative trait locus analysis, pathway analysis, and consomic mapping show genetic variants of TNNI3K, FPGT, or H28 control susceptibility to viral myocarditis. J Immunol 2011; 186: 6398-6405.
33. Wei YJ, Cui CJ, Huang YX, Zhang XL, Zhang H, Hu SS. Upregulated expression of cardiac ankyrin repeat protein in human failing hearts due to arrhythmogenic right ventricular cardiomyopathy. Eur J Heart Fail 2009; 11: 559-566.
34. Lodder EM, Scicluna BP, Milano A, Sun AY, Tang H, Remme CA, et al. Dissection of a quantitative trait locus for PR interval duration identifies TNNI3K as a novel modulator of cardiac conduction. PLoS Genet 2012; 8: e1003113, doi:org/10.1371/journal.pgen.1003113.
35. Curran J, Mohler PJ. Defining the pathways underlying the prolonged PR interval in atrioventricular conduction disease. PLoS Genet 2012; 8: e1003154, doi:org/10.1371/journal.pgen.1003154.
36. Cornelis MC, Rimm EB, Curhan GC, Kraft P, Hunter DJ, Hu FB, et al. Obesity susceptibility loci and uncontrolled eating, emotional eating and cognitive restraint behaviors in men and women. Obesity (Silver Spring) 2014; 22: E135-E141, doi:org/10.1002/oby.20592.
37. Graff M, Ngwa JS, Workalemahu T, Homuth G, Schipf S, Teumer A, et al. Genome-wide analysis of BMI in adolescents and young adults reveals additional insight into the effects of genetic loci over the life course. Hum Mol Genet 2013; 22: 3597-3607.
38. McCaffery JM, Papandonatos GD, Peter I, Huggins GS, Raynor HA, Delahanty LM, et al. Obesity susceptibility loci and dietary intake in the Look AHEAD trial. Am J Clin Nutr 2012; 95: 1477-1486.
39. Zhao J, Bradfield JP, Zhang H, Sleiman PM, Kim CE, Glessner JT, et al. Role of BMI-associated loci identified in GWAS meta-analyses in the context of common childhood obesity in European Americans. Obesity (Silver Spring) 2011; 19: 2436-2439.